Gilead Sciences Inc Asset Resilience Ratio
Gilead Sciences Inc asset resilience ratio. Gilead Sciences Inc (GILD) has an Asset Resilience Ratio of 0.00% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Gilead Sciences Inc (GILD) liquidity interval to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Gilead Sciences Inc (1999–2025)
Asset resilience ratio of Gilead Sciences Inc from 1999 to 2025. This chart shows how Gilead Sciences Inc's Asset Resilience Ratio has changed over time. Read Gilead Sciences Inc total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Gilead Sciences Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see GILD asset base.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $0.00 | 0% |
| Total Liquid Assets | $0.00 | 0.00% |
Asset Resilience Insights
- Limited Liquidity: Gilead Sciences Inc maintains only 0.00% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company maintains a balanced mix of cash and short-term investments.
Gilead Sciences Inc Industry Peers by Asset Resilience Ratio
Compare Gilead Sciences Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Novartis AG
SW:NOVN |
Drug Manufacturers - General | 0.08% |
|
Virbac SA
PA:VIRP |
Drug Manufacturers - General | 0.23% |
|
AstraZeneca PLC
LSE:AZN |
Drug Manufacturers - General | 0.06% |
|
Zhejiang Int'L Group Co Ltd
SHE:000411 |
Drug Manufacturers - General | 0.00% |
|
GuangYuYuan Chinese Herbal Medicine Co Ltd
SHG:600771 |
Drug Manufacturers - General | 1.97% |
|
Hubei Guangji Pharmaceutical Co Ltd
SHE:000952 |
Drug Manufacturers - General | 5.37% |
|
Firebrick Pharma Ltd
AU:FRE |
Drug Manufacturers - General | 0.29% |
|
Eli Lilly and Company
SA:LILY34 |
Drug Manufacturers - General | 6.46% |
Gilead Sciences Inc Asset Resilience Ratio by Year (1999–2025)
Gilead Sciences Inc asset resilience ratio by year from 1999 to 2025. The table below shows the annual Asset Resilience Ratio data for Gilead Sciences Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 3.47% | $2.05 Billion | $59.02 Billion | +0.80pp |
| 2024-12-31 | 2.67% | $1.58 Billion | $58.99 Billion | +0.78pp |
| 2023-12-31 | 1.90% | $1.18 Billion | $62.12 Billion | +0.36pp |
| 2022-12-31 | 1.54% | $973.00 Million | $63.17 Billion | -0.20pp |
| 2021-12-31 | 1.74% | $1.18 Billion | $67.95 Billion | -0.32pp |
| 2020-12-31 | 2.06% | $1.41 Billion | $68.41 Billion | -18.58pp |
| 2019-12-31 | 20.64% | $12.72 Billion | $61.63 Billion | +1.56pp |
| 2018-12-31 | 19.08% | $12.15 Billion | $63.67 Billion | -6.42pp |
| 2017-12-31 | 25.50% | $17.92 Billion | $70.28 Billion | +19.07pp |
| 2016-12-31 | 6.43% | $3.67 Billion | $56.98 Billion | +3.05pp |
| 2015-12-31 | 3.39% | $1.76 Billion | $51.84 Billion | +3.10pp |
| 2014-12-31 | 0.29% | $101.00 Million | $34.66 Billion | +0.21pp |
| 2013-12-31 | 0.08% | $19.00 Million | $22.58 Billion | -0.19pp |
| 2012-12-31 | 0.28% | $58.56 Million | $21.24 Billion | +0.18pp |
| 2011-12-31 | 0.10% | $16.49 Million | $17.30 Billion | -10.18pp |
| 2010-12-31 | 10.27% | $1.19 Billion | $11.59 Billion | +6.31pp |
| 2009-12-31 | 3.96% | $384.02 Million | $9.70 Billion | -0.81pp |
| 2008-12-31 | 4.77% | $330.76 Million | $6.94 Billion | +1.27pp |
| 2007-12-31 | 3.49% | $203.89 Million | $5.83 Billion | +0.54pp |
| 2006-12-31 | 2.96% | $120.84 Million | $4.09 Billion | -39.61pp |
| 2005-12-31 | 42.56% | $1.60 Billion | $3.77 Billion | -2.57pp |
| 2004-12-31 | 45.14% | $973.13 Million | $2.16 Billion | +12.19pp |
| 2003-12-31 | 32.95% | $512.28 Million | $1.55 Billion | +7.69pp |
| 2002-12-31 | 25.26% | $325.44 Million | $1.29 Billion | -32.53pp |
| 2001-12-31 | 57.80% | $459.36 Million | $794.79 Million | +11.26pp |
| 2000-12-31 | 46.54% | $315.59 Million | $678.10 Million | -10.09pp |
| 1999-12-31 | 56.63% | $247.38 Million | $436.81 Million | -- |
About Gilead Sciences Inc
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Descovy, Genvoya, Odefsey, Sunlenca, Symtuza, and YeztugoFor the treatment of HIV-1 infection in patients. It also provides Epclusa, Livdelzi, and Vemlidy to treat chronic hepatiti… Read more